376 related articles for article (PubMed ID: 25899606)
21. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Zhang L; Zhang ZG; Zhang C; Zhang RL; Chopp M
Stroke; 2004 Dec; 35(12):2890-5. PubMed ID: 15514182
[TBL] [Abstract][Full Text] [Related]
22. MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.
Ding G; Zhang Z; Chopp M; Li L; Zhang L; Li Q; Wei M; Jiang Q
Neuroscience; 2014 Jun; 271():1-8. PubMed ID: 24769225
[TBL] [Abstract][Full Text] [Related]
23. Tissue plasminogen activator extravasated through the cerebral vessels: evaluation using a rat thromboembolic stroke model.
Harada T; Kano T; Katayama Y; Matsuzaki T; Tejima E; Koshinaga M
Thromb Haemost; 2005 Oct; 94(4):791-6. PubMed ID: 16270632
[TBL] [Abstract][Full Text] [Related]
24. Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: an effective treatment for reperfusion injury following acute ischemic stroke in rats.
Turner RJ; Vink R
Neuroscience; 2012 Sep; 220():1-10. PubMed ID: 22750240
[TBL] [Abstract][Full Text] [Related]
25. Detrimental effects of post-treatment with fatty acids on brain injury in ischemic rats.
Yang DY; Pan HC; Yen YJ; Wang CC; Chuang YH; Chen SY; Lin SY; Liao SL; Raung SL; Wu CW; Chou MC; Chiang AN; Chen CJ
Neurotoxicology; 2007 Nov; 28(6):1220-9. PubMed ID: 17854901
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
[TBL] [Abstract][Full Text] [Related]
27. Safety of low-frequency transcranial ultrasound in permanent middle cerebral artery occlusion in spontaneously hypertensive rats.
Wang Z; Fukuda T; Azuma T; Furuhata H
Cerebrovasc Dis; 2012; 33(1):23-9. PubMed ID: 22133698
[TBL] [Abstract][Full Text] [Related]
28. The role of connexin43 in hemorrhagic transformation after thrombolysis in vivo and in vitro.
Yang X; Chu H; Tang Y; Dong Q
Neuroscience; 2016 Aug; 329():54-65. PubMed ID: 27138645
[TBL] [Abstract][Full Text] [Related]
29. Curcumin by down-regulating NF-kB and elevating Nrf2, reduces brain edema and neurological dysfunction after cerebral I/R.
Li W; Suwanwela NC; Patumraj S
Microvasc Res; 2016 Jul; 106():117-27. PubMed ID: 26686249
[TBL] [Abstract][Full Text] [Related]
30. Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats.
Murakami K; Suzuki M; Suzuki N; Hamajo K; Tsukamoto T; Shimojo M
Brain Res; 2013 Aug; 1526():84-93. PubMed ID: 23791950
[TBL] [Abstract][Full Text] [Related]
31. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor.
Ding G; Jiang Q; Zhang L; Zhang ZG; Li L; Knight RA; Ewing JR; Wang Y; Chopp M
J Cereb Blood Flow Metab; 2005 Jan; 25(1):87-97. PubMed ID: 15678115
[TBL] [Abstract][Full Text] [Related]
32. Tetramethylpyrazine-2'-O-sodium ferulate attenuates blood-brain barrier disruption and brain oedema after cerebral ischemia/reperfusion.
Xu SH; Yin MS; Liu B; Chen ML; He GW; Zhou PP; Cui YJ; Yang D; Wu YL
Hum Exp Toxicol; 2017 Jul; 36(7):670-680. PubMed ID: 27387348
[TBL] [Abstract][Full Text] [Related]
33. Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Jin R; Xiao AY; Liu S; Wang M; Li G
Stroke; 2018 Jul; 49(7):1708-1718. PubMed ID: 29844028
[TBL] [Abstract][Full Text] [Related]
34. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience.
Aronowski J; Strong R; Shirzadi A; Grotta JC
Stroke; 2003 May; 34(5):1246-51. PubMed ID: 12690223
[TBL] [Abstract][Full Text] [Related]
35. Treatment with tPA predicts better outcome even if MCA occlusion persists.
Kablau M; Alonso A; Hennerici MG; Fatar M
Int J Stroke; 2013 Oct; 8(7):496-502. PubMed ID: 22340025
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermia masks the neuroprotective effects of tissue plaminogen activator.
Noor R; Wang CX; Shuaib A
Stroke; 2005 Mar; 36(3):665-9. PubMed ID: 15705940
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Zhang L; Zhang ZG; Zhang R; Morris D; Lu M; Coller BS; Chopp M
Circulation; 2003 Jun; 107(22):2837-43. PubMed ID: 12756151
[TBL] [Abstract][Full Text] [Related]
38. Tissue plasminogen activator treatment of stroke in type-1 diabetes rats.
Ning R; Chopp M; Yan T; Zacharek A; Zhang C; Roberts C; Cui X; Lu M; Chen J
Neuroscience; 2012 Oct; 222():326-32. PubMed ID: 22820263
[TBL] [Abstract][Full Text] [Related]
39. Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
Esmaeeli-Nadimi A; Kennedy D; Allahtavakoli M
Eur J Pharmacol; 2015 Oct; 764():55-62. PubMed ID: 26123846
[TBL] [Abstract][Full Text] [Related]
40. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Alvarez-Sabín J; Molina CA; Montaner J; Arenillas JF; Huertas R; Ribo M; Codina A; Quintana M
Stroke; 2003 May; 34(5):1235-41. PubMed ID: 12677014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
